Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722839 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants
A Phase 1 study of Nonneoplastic Condition, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT00722839: Completed Phase 1 study of Nonneoplastic Condition, sponsored by City of Hope Medical Center.
NCT00722839 is a Phase 1 study of Nonneoplastic Condition that has completed, run by City of Hope Medical Center. The registered enrollment target is 68 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00722839, a Phase 1 study of Nonneoplastic Condition, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines made from peptides may help the body build an immune response to kill cytomegalovirus. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in preventing cytomegalovirus in healthy participants.
Conditions Studied
Interventions
- BIOLOGICAL PADRE-CMV fusion peptide vaccine
- BIOLOGICAL tetanus-CMV fusion peptide vaccine
- DRUG agatolimod sodium
Study Locations (1)
California
- City of Hope Comprehensive Cancer Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2006-12 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
What the finished NCT00722839 record still lists
NCT00722839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% higher).
The record links to 1 condition, with Nonneoplastic Condition appearing as the primary indexed condition, and to 3 interventions - of which PADRE-CMV fusion peptide vaccine is the first listed.
NCT00722839 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00722839 about?
NCT00722839 is a clinical study titled "Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants". RATIONALE: Vaccines made from peptides may help the body build an immune response to kill cytomegalovirus. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in preventing cytomegalovirus in healthy participants.
What is the current status of trial NCT00722839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2006-12. Estimated completion is 2012-04.
What conditions does trial NCT00722839 study?
This clinical trial studies the following conditions: Nonneoplastic Condition.
What interventions are being tested in trial NCT00722839?
The interventions under investigation include: PADRE-CMV fusion peptide vaccine (BIOLOGICAL), tetanus-CMV fusion peptide vaccine (BIOLOGICAL), agatolimod sodium (DRUG).
Who is sponsoring clinical trial NCT00722839?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00722839 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00722839's enrollment target sits among peer trials
68 776th of 2000 higher than 1,219 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia